Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
about
Best Practices in Chronic Myeloid Leukemia Monitoring and ManagementDifferential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.The Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia.Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.Bosutinib for Chronic Myeloid Leukemia.How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.Ponatinib in the therapy of chronic myeloid leukemia.Anoikis and EMT: Lethal "Liaisons" during Cancer Progression.Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity.Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.Practical Management of Toxicities Associated With Bosutinib in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.Bosutinib in chronic myeloid leukemia: patient selection and perspectives.Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
P2860
Q36884361-B2A7B9B7-5B4A-4D42-9698-35C94BD6ED51Q37027098-F6650138-F18F-4676-A287-2B1446B62456Q38598820-A2D8D06B-9A2E-405E-A6A1-AD057E5AC945Q38642952-675D27B0-8892-42D1-905B-04314D94F789Q38707841-FE7AB165-2F24-40BA-ACF2-337FF0E59BEFQ38739574-3946EB31-C394-4259-B1C5-D1D80F9FF0B6Q38757051-DDAC6D78-7579-4079-85B4-A16F11581605Q38767908-F3C56444-8B1F-4FAC-9B2E-44001279EF4DQ38829019-2A79E8E3-4B78-4A41-8D83-B08EA82C7D43Q38835127-C39B9B22-FB3E-41BF-8C7A-EEA9ACD34B16Q38845834-643684C2-26AB-4245-A9B6-41020BA6CC14Q38945162-F3674090-CAF7-4626-AB03-EE485036EA54Q39028687-B45F5DAF-B728-4F54-A69B-6ADB23187ED4Q39339523-984614B4-05D1-4CC3-9391-16CAC05D61FBQ39457369-640F6DD5-F679-464F-A249-81E62BC84870Q48275281-968BCEB7-C97C-413A-AA2C-337DF689A40DQ49553324-8EA13076-5983-40B4-8741-596FC299C1F8Q52562694-1609C10B-01D7-43AF-87F5-2F3461063DE4Q52641875-AEF3AF6B-06F7-4751-A4A2-E2F2B3328C5DQ52816089-33F4EFA3-7F8B-4E73-B329-217CC5F92F31
P2860
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term efficacy and safety ...... er tyrosine kinase inhibitors.
@en
Long-term efficacy and safety ...... er tyrosine kinase inhibitors.
@nl
type
label
Long-term efficacy and safety ...... er tyrosine kinase inhibitors.
@en
Long-term efficacy and safety ...... er tyrosine kinase inhibitors.
@nl
prefLabel
Long-term efficacy and safety ...... er tyrosine kinase inhibitors.
@en
Long-term efficacy and safety ...... er tyrosine kinase inhibitors.
@nl
P2093
P2860
P50
P356
P1476
Long-term efficacy and safety ...... er tyrosine kinase inhibitors.
@en
P2093
Dong-Wook Kim
Ewa Matczak
Hanna J Khoury
Kathleen Turnbull
Mark Shapiro
Nathalie Bardy-Bouxin
Tim H Brümmendorf
P2860
P304
P356
10.1002/AJH.24034
P577
2015-06-01T00:00:00Z